Akebia Therapeutics financials
$0.8861−0.78%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $236.2M | $160.2M | $194.6M | $292.5M | $211.7M | $294.6M | $335.0M | $207.7M | $181.2M | $1.5M |
| Gross profit | $196.7M | $97.0M | $120.5M | $206.9M | $61.0M | -$1.8M | $189.7M | $200.0M | $181.2M | $1.5M |
| Gross margin | 83.3% | 60.6% | 61.9% | 70.7% | 28.8% | −0.6% | 56.6% | 96.3% | 100.0% | 100.0% |
| Operating income | $23.5M | -$50.5M | -$46.3M | -$80.8M | -$264.5M | -$377.8M | -$286.3M | -$178.2M | -$76.7M | -$136.5M |
| Net income | -$5.3M | -$69.4M | -$51.9M | -$94.2M | -$282.0M | -$384.8M | -$279.7M | -$143.6M | -$73.7M | -$135.7M |
| Net margin | −2.3% | −43.3% | −26.7% | −32.2% | −133.3% | −130.6% | −83.5% | −69.1% | −40.7% | −8843.5% |
| Diluted EPS | $-0.02 | $-0.33 | $-0.28 | $-0.52 | $-1.70 | $-2.78 | $-2.36 | $-2.47 | $-1.69 | $-3.60 |
| EBITDA | $24.8M | -$12.9M | -$8.4M | -$27.1M | -$226.5M | -$343.1M | -$247.6M | -$175.7M | -$76.1M | -$136.2M |
| Operating cash flow | $68.0M | -$40.7M | -$23.4M | -$73.2M | -$253.0M | -$110.4M | -$257.4M | -$97.5M | -$56.2M | $57.9M |
| Free cash flow | $67.7M | -$40.7M | -$23.4M | -$73.3M | -$253.0M | -$110.7M | -$264.1M | -$99.1M | -$57.8M | $55.2M |
| Diluted shares | 257.2M | 210.9M | 187.5M | 182.8M | 165.9M | 138.5M | 118.4M | 58.0M | 43.5M | 37.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $184.8M | $51.9M | $42.9M | $90.5M | $149.8M | $228.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | $40.0M |
| Total debt | $48.3M | $38.7M | $34.7M | $66.1M | $97.5M | $96.4M |
| Total assets | $376.6M | $220.7M | $241.7M | $356.1M | $529.3M | $644.1M |
| Total liabilities | $344.0M | $269.9M | $272.3M | $350.8M | $455.3M | $396.5M |
| Shareholders' equity | $32.6M | -$49.2M | -$30.6M | $5.2M | $74.0M | $247.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology